Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, optimistic guidance, and strategic product development, especially with AMDS and NEXUS. The Q&A section highlights management's confidence in market opportunities and competitive positioning. Despite some unclear responses, the overall tone is positive. With a market cap of ~$1 billion, the stock is likely to see a positive reaction, in the 2% to 8% range, over the next two weeks.
Key Financial Performance
Total adjusted constant currency revenue growth (2025) 13%, driven by strong performance across the product portfolio and operational excellence.
Adjusted EBITDA growth (2025) 26%, attributed to operational leverage and investment in growth initiatives.
Stent grafts revenue growth (Q4 2025) 36% year-over-year, driven by AMDS in the U.S., international growth, and easier comparisons due to a prior cybersecurity incident.
On-X revenue growth (Q4 2025) 24% year-over-year, supported by global market share gains and new U.S. market opportunities from clinical data.
Tissue processing revenue growth (Q4 2025) 6% year-over-year, recovering from the prior year's cybersecurity incident.
BioGlue revenue growth (Q4 2025) Flat year-over-year, with variability due to stocking distributor business.
Total adjusted revenues (Q4 2025) $118.3 million, up 18.5% year-over-year, excluding the Italian payback adjustment.
Adjusted EBITDA (Q4 2025) $22.7 million, a 29% increase from $17.6 million in Q4 2024, driven by SG&A leverage.
Adjusted EBITDA margin (Q4 2025) 19.2%, an improvement of approximately 110 basis points year-over-year.
Regional revenue growth (Q4 2025) Asia Pacific: 32%, North America: 18%, EMEA: 17%, Latin America: 9%, driven by strong product performance.
Gross margins (Q4 2025) 63%, consistent with Q4 2024, with impacts from the Italian payback adjustment and manufacturing inefficiencies.
Free cash flow (2025) Approximately $1 million, despite $20 million in one-time cash payments for facility purchases.
Net leverage ratio (2025) 1.8, reduced from 3.8 in the prior year, reflecting improved financial health.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Stent Grafts: Achieved 36% growth in Q4 2025, driven by AMDS in the U.S. and international growth. Plans to expand stent graft products from Europe to the U.S. and Japan to increase market share.
On-X Heart Valves: Revenue grew 24% in Q4 2025 due to global market share gains and new $100 million U.S. market opportunity supported by clinical data.
BioGlue: Revenue remained flat in Q4 2025, with variability expected due to distributor stocking.
Regional Revenue Growth: Asia Pacific grew 32%, North America 18%, EMEA 17%, and Latin America 9% in Q4 2025.
New Market Opportunities: AMDS targets a $150 million U.S. market, On-X targets a $100 million U.S. market, and NEXUS targets a $150 million U.S. market.
Revenue Growth: Achieved 13% constant currency revenue growth for 2025, with adjusted EBITDA growth of 26%.
Operational Efficiencies: Improved adjusted EBITDA margin by 190 basis points in 2025, leveraging SG&A and managing R&D expenses.
Clinical Trials and Approvals: Progressed on AMDS PMA filing, NEXUS TRIOMPHE trial, and ARTIZEN IDE trial, targeting significant market opportunities.
Cybersecurity Recovery: Recovered from 2024 cybersecurity incident, with impacted product lines showing growth in 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cybersecurity Incident: The cybersecurity incident in Q4 2024 negatively impacted the stent graft and Preservation Services businesses, causing revenue disruptions. Lingering effects were noted in Q1 2025, impacting tissue processing growth.
Italian Payback Legislation: The Italian government's legislation requiring medical device companies to pay back a portion of revenue when healthcare budgets are exceeded resulted in a $2.3 million adjustment to revenue for fiscal years 2019-2025. This law will continue to impact the company, albeit minimally, beyond 2025.
Tissue Processing Revenue Decline: Tissue processing revenue declined 3% for the full year 2025, below expectations, primarily due to the lingering impact of the cybersecurity incident.
Manufacturing Inefficiencies: Certain manufacturing inefficiencies negatively impacted gross margins in 2025, though these are not expected to repeat in 2026.
Regulatory and Clinical Trial Risks: The company faces risks related to the approval timelines and outcomes of clinical trials for products like AMDS, NEXUS, and Arcevo LSA. Delays or failures in these trials could impact future revenue and market opportunities.
Capital Expenditure Increase: Elevated capital expenditures in 2025 and 2026, driven by investments in facilities and equipment for On-X growth, could strain cash flow in the short term.
Flat Tissue Business in 2026: The company expects the tissue business to remain flat in 2026, indicating limited growth potential in this segment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Stent Graft Expansion: Artivion plans to bring additional stent graft products, already generating revenue in Europe, to the U.S. and Japan, aiming to expand the total addressable market for stent grafts.
On-X Heart Valve Growth: The company expects continued global market share gains for On-X, supported by new clinical data demonstrating improved outcomes for patients under 65 years old. This represents a $100 million U.S. market opportunity.
AMDS PMA Approval: Artivion has filed the final module with the FDA for AMDS, targeting approval by mid-2026. The company is focused on penetrating the $150 million annual U.S. market opportunity for AMDS.
NEXUS Aortic Arch Stent Graft System: Positive clinical trial data supports the NEXUS system, with FDA approval anticipated in the second half of 2026. This represents a $150 million annual U.S. market opportunity.
ARTIZEN IDE Trial: The ARTIZEN trial for the Arcevo LSA product is ongoing, with full enrollment expected by mid-2027. FDA approval is anticipated in 2029, unlocking an $80 million annual U.S. market opportunity.
2026 Revenue Growth: Artivion projects constant currency revenue growth of 10% to 14% for 2026, with a revenue range of $486 million to $504 million.
Adjusted EBITDA Growth: The company expects adjusted EBITDA growth of 18% to 22% in 2026, with a margin expansion of approximately 150 basis points.
Capital Expenditures: CapEx is expected to increase to $50 million in 2026, up from $39 million in 2025, driven by investments in facilities and equipment to support long-term growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you clarify the impact of the Italian clawback on the financials, specifically whether it affected U.S. or OUS numbers and any specific products?
A:The Italian clawback was in OUS, specifically in the EMEA line, and was reported in the 'other' line item of revenue. It did not impact the big 4 line items or skew their growth rates. The main difference in U.S. growth rates from Q3 to Q4 was due to the tissue business, which had a lower growth rate in Q4 after adjusting for the cybersecurity event.
Q:Can you provide commentary on the sell-in versus sell-through for AMDS and the guidance for AMDS and On-X?
A:Management does not typically break out details on AMDS revenue or new account start-ups versus implantations. However, implantations are growing well, and the first experience for surgeons has been positive. Guidance for AMDS and On-X remains strong.
Q:What progress has been made on AMDS target accounts, and what should we expect as 2026 plays out with full FDA approval?
A:AMDS is still in the early stages, with only 10% of target accounts opened. 2025 focused on opening accounts, and 2026 will involve opening more accounts and increasing implantations in existing accounts. Management is optimistic about growth in 2026.
Q:Can you provide insights on the NEXUS market opportunity and its competitive positioning?
A:The U.S. market for NEXUS is estimated at $150 million. It targets high-risk patients unsuitable for open surgery, similar to early TAVR. NEXUS is seen as a platform technology with potential to expand the market. Management believes it is well-positioned to compete with the existing approved device and expects PMA approval in the second half of the year.
Q:What are your thoughts on pricing for AMDS and NEXUS, and are the assumptions of $25,000 for AMDS and $50,000 for NEXUS still valid?
A:Management believes the pricing assumptions are valid, as these are cutting-edge, life-saving therapies with favorable reimbursement backgrounds.
Q:What are the assumptions behind the 10% to 14% CAGR guidance, and what factors could influence the range?
A:The guidance assumes flat growth for tissue, mid-single-digit growth for Glue, mid-teens growth for On-X, and low 20s growth for stents. Upside potential lies in driving On-X adoption and opening more AMDS accounts, which could push growth to the higher end of the range.
Q:Has the implementation of DRG 209 accelerated VAC approvals or shortened the time frame from IRB to first case?
A:The new DRG 209 is seen as a tailwind but has not significantly accelerated hospital bureaucracy. It makes conversations easier but does not drastically change the pace of approvals.
Q:What is the timing for launching a formal marketing program to cardiologists for On-X?
A:Management is optimistic about the potential of On-X and has several programs in place to educate cardiologists. The timing and impact will become clearer as these programs progress through 2026.
Q:Will the PMA for AMDS impact its growth, and what is the status of AMDS in Japan?
A:The PMA will remove administrative hurdles like local IRB requirements but is not expected to meaningfully change growth. Japan's approval process will begin after the U.S. PMA, with updates expected midyear.
Q:What is the reason for the $50 million CapEx guidance, and is it primarily for On-X capacity expansion?
A:The higher CapEx is primarily for On-X capacity expansion and increased investment in IT systems to improve efficiency. CapEx is expected to decrease after 2027 but remain above historical levels.
Q:Are you still seeing cross-selling benefits between AMDS and On-X, and what trends are emerging with new surgeons?
A:Cross-selling benefits continue as new AMDS accounts open, leading to increased On-X adoption. Relationships with surgeons are helping to drive this trend.
Q:What are the nuances of the NEXUS commercial rollout compared to AMDS?
A:NEXUS requires more intensive training and is targeted at a smaller number of highly skilled vascular surgeons in major centers. AMDS, in contrast, is easier to use and has a broader target audience.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on AMDS revenue breakdown, new account start-ups versus implantations, and the exact impact of DRG 209 on hospital bureaucracy. Additionally, they did not provide a clear timeline for the formal marketing program for On-X or specific updates on Japan's AMDS approval process.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMDS PERSEVERE
AMDS comp
AMDS module
America reminder
Artivion End
Artivion position
Artivion progress
COO CFO
Mackin
RD percentage
RD sale
adjustment payback
afternoon Artivion
benefit AMDS
conference
currency rate
cyber incident
device company
facility
government
graft tissue
impact cyber
incident stent
increase RD
legislation
margin basis
margin percentage
payback adjustment
percentage point
percentage sale
point improvement
quarter
rate mid
revenue cyber
revenue tissue
stroke
system
treatment dissection
year law
AORT Transcript
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call reveals strong financial performance, optimistic guidance, and strategic product development, especially with AMDS and NEXUS. The Q&A section highlights management's confidence in market opportunities and competitive positioning. Despite some unclear responses, the overall tone is positive. With a market cap of ~$1 billion, the stock is likely to see a positive reaction, in the 2% to 8% range, over the next two weeks.
Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript
Positive11-6
The company shows strong growth across product lines, increased revenue guidance, and improved EBITDA margins. The Q&A reveals excitement around On-X's unique clinical data and AMDS's strong demand. Although management avoided specific 2026 guidance, the positive outlook for product launches and market expansions supports a positive sentiment. With a market cap of approximately $1 billion, the stock is likely to react positively, with a predicted movement of 2% to 8%.
Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-10
Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong financial performance with revenue and EBITDA growth, successful product launches, and raised guidance. Positive market sentiment is reinforced by strong regional revenue growth and improved leverage ratios. The Q&A section highlights effective product adoption and cross-selling, though some specifics were lacking. Considering the company's small-cap status, the positive performance and guidance suggest a likely stock price increase of 2% to 8%.
AORT Slides
AORT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
